New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
16:24 EDTBMRN, REGNBioMarin sells priority review voucher for $67.5M to Regeneron
BioMarin Pharmaceutical (BMRN) announced that it has sold the Rare Pediatric Disease Priority Review Voucher it obtained in February of this year. The company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5M from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals (REGN), in exchange for the voucher. "Leveraging the sale of the Priority Review Voucher to reinvest in products to treat rare and ultra-rare diseases makes the most sense for BioMarin given our stage of growth," said Jean-Jacques Bienaimé, CEO of BioMarin.
News For BMRN;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:00 EDTBMRNPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
08:19 EDTBMRNBioMarin price target raised to $150 from $125 at Cowen
Cowen raised its price target on BioMarin to $150 from $125 on the company's BMN-111 potential. The firm believes successful proof of concept may take time, warranting investors to be patient. Cowen reiterated its Outperform rating on BioMarin shares.
May 27, 2015
06:30 EDTBMRNBioMarin price target raised to $140 from $125 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for BioMarin shares to $140 from $125 and reiterates an Overweight rating on the stock ahead of data for BMN-111 in dwarfism later on in Q2 and other pipeline catalysts this year. Kasimov sees potential for "material" share upside despite the 41% rally year-to-date and says BioMarin remains one of his top picks. The stock closed yesterday down 8c to $127.11.
May 21, 2015
14:48 EDTREGNRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
05:15 EDTREGNRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 20, 2015
15:42 EDTBMRNTheStreetSweeper says short Sarepta
The Street Sweeper stated on Twitter that Sarepta (SRPT) has a "long way to go" and "We’re short." It also noted that Canaccord says if BioMarin's (BMRN) DMD drug is approved first that the pressure to approve Sarepta's “may decrease.” Reference Link
11:46 EDTBMRNBioMarin sees self as buyer, not acquisition candidate, dealReporter says
Subscribe for More Information
10:22 EDTBMRNSarepta soars after FDA agrees to accept DMD drug submission
The shares of Sarepta Therapeutics (SRPT) are rallying after the company announced that, following meetings with the FDA, it would submit its eteplirsen drug for the agency's approval. Last October, the FDA said the company would have to submit more data on the drug before the agency would consider approving the treatment. WHAT'S NEW: Sarepta announced last night that it would submit its eteplirsen to the FDA for approval. The submission will be done on a rolling basis, with various components of the application being submitted separately. Eteplirsen is a treatment for Duchenne muscular dystrophy or DMD. ANALYST REACTION: Roth Capital analyst Debjit Chattopadhyay responded to the news by more than doubling his price target on Sarepta to $45 from $22. The analyst is upbeat on Sarepta's approach of seeking to address DMD patients' lack of dystrophin, which he calls the patients' primary biochemical defect. He predicts that both eteplirsen and another DMD treatment, BioMarin's (BMRN) drisapersen, will be recommended for approval at a joint panel meeting in the second half of 2015. While both drugs are likely to be approved, BioMarin's decision to not yet initiate new studies on its DMD treatment has placed Sarepta in the pole position, Chattopadhyay believes. BioMarin will have to run additional studies and if both drugs are approved, BioMarin will find it difficult to recruit patients due to drisapersen's safety profile, according to the analyst. Chattopadhyay continues to believe that Sarepta's PMO platform will be the winner in DMD and he kept a Buy rating on the stock. More upbeat on BioMarin was Jefferies analyst Eun Yang. After meeting with BioMarin's management, the analyst reported that the company's confidence has increased following its pre-submission discussions with the FDA. If the FDA approves drisapersen on a non-accelerated basis, BioMarin may not be required to conduct any additional studies, the analyst stated. Yang sees a 60% chance of the drug being approved and believes that the stock would rise more than 25% if approval is granted. The analyst kept a $135 price target and Buy rating on BioMarin shares. PRICE ACTION: In early trading Sarepta climbed 45% to $23.81 and BioMarin was little changed at $125 per share.
09:10 EDTBMRNSarepta price target raised to $43 from $34 at William Blair
Subscribe for More Information
09:05 EDTBMRNSarepta price target raised to $45 from $22 at Roth Capital
Subscribe for More Information
08:53 EDTREGNRegeneron price target raised to $560 from $500 at Argus
Argus increased its price target on Regeneron as the firm notes that the company has had positive pipeline and earnings news over the past year, and has increased its sales outlook. Argus thinks the company has a strong pipeline and keeps a Buy rating on the shares.
07:48 EDTBMRNBioMarin has a conference call hosted by JPMorgan
Subscribe for More Information
07:38 EDTREGNRegeneron price target raised to $600 from $525 at Canaccord
Canaccord raised its price target on Regeneron to $600 from $525 following positive top-line data for its Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma. The firm sees the data as significant, as it reinforces the role of dupilumab and increases the potential future revenue stream for the company. Canaccord reiterated its Buy rating on Regeneron shares.
07:17 EDTBMRNBioMarin can rally over 25% on drisapersen approval, says Jefferies
Jefferies analyst Eun Yang sees greater than 25% upside in shares of BioMarin should the FDA approve drisapersen for Duchenne muscular dystrophy. After hosting an investor dinner with management, Yang says BioMarin's confidence in drisapersen approvability has increased. The analyst's model, which includes a price target for shares of $135 and a Buy rating, assumes 60% probability of approval for drisapersen. Shares of BioMarin closed yesterday down $1.03 to $124.99.
May 18, 2015
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
May 15, 2015
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use